메뉴 건너뛰기




Volumn 12, Issue 11, 2015, Pages 631-644

Clinical overview of metronomic chemotherapy in breast cancer

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; BEVACIZUMAB; BIOLOGICAL MARKER; CANCER VACCINE; CAPECITABINE; CELECOXIB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DPX SURVIVAC VACCINE; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FULVESTRANT; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; NANOPARTICLE; NAVELBINE; PACLITAXEL; PREDNISONE; TEMOZOLOMIDE; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

EID: 84946474811     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.131     Document Type: Review
Times cited : (123)

References (147)
  • 1
    • 0034048358 scopus 로고    scopus 로고
    • Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
    • Hanahan, D., Bergers, G. & Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105, 1045-1047 (2000).
    • (2000) J. Clin. Invest. , vol.105 , pp. 1045-1047
    • Hanahan, D.1    Bergers, G.2    Bergsland, E.3
  • 2
    • 0034032882 scopus 로고    scopus 로고
    • Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
    • Browder, T. et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878-1886 (2000).
    • (2000) Cancer Res. , vol.60 , pp. 1878-1886
    • Browder, T.1
  • 3
    • 0034087691 scopus 로고    scopus 로고
    • Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
    • Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15-R24 (2000).
    • (2000) J. Clin. Invest. , vol.105 , pp. R15-R24
    • Klement, G.1
  • 4
    • 0036225350 scopus 로고    scopus 로고
    • Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels
    • Colleoni, M. et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 13, 73-80 (2002).
    • (2002) Ann. Oncol. , vol.13 , pp. 73-80
    • Colleoni, M.1
  • 5
    • 33748463225 scopus 로고    scopus 로고
    • Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer
    • Orlando, L. et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs. 17, 961-967 (2006).
    • (2006) Anticancer Drugs. , vol.17 , pp. 961-967
    • Orlando, L.1
  • 7
    • 84929514070 scopus 로고    scopus 로고
    • Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): A phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
    • Simkens, L. H. et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 385, 1843-1852 (2015).
    • (2015) Lancet , vol.385 , pp. 1843-1852
    • Simkens, L.H.1
  • 8
    • 2942615257 scopus 로고    scopus 로고
    • The anti-angiogenic basis of metronomic chemotherapy
    • Kerbel, R. S. & Kamen, B. A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4, 423-436 (2004).
    • (2004) Nat. Rev. Cancer , vol.4 , pp. 423-436
    • Kerbel, R.S.1    Kamen, B.A.2
  • 9
    • 78650796469 scopus 로고    scopus 로고
    • Nontoxic fiscally responsible, future of oncology: Could it be beginning in the Third World?
    • Klement, G. L. & Kamen, B. A. Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? J. Pediatr. Hematol. Oncol. 33, 1-3 (2011).
    • (2011) J. Pediatr. Hematol. Oncol. , vol.33 , pp. 1-3
    • Klement, G.L.1    Kamen, B.A.2
  • 10
    • 77955172181 scopus 로고    scopus 로고
    • Metronomic chemotherapy: New rationale for new directions
    • Pasquier, E., Kavallaris, M. & André, N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 7, 455-465 (2010).
    • (2010) Nat. Rev. Clin. Oncol. , vol.7 , pp. 455-465
    • Pasquier, E.1    Kavallaris, M.2    André, N.3
  • 11
    • 0034243694 scopus 로고    scopus 로고
    • High-time chemotherapy or high time for low dose
    • Kamen, B. A., Rubin, E., Aisner, J. & Glatstein, E. High-time chemotherapy or high time for low dose. J. Clin. Oncol. 18, 2935-2937 (2000).
    • (2000) J. Clin. Oncol. , vol.18 , pp. 2935-2937
    • Kamen, B.A.1    Rubin, E.2    Aisner, J.3    Glatstein, E.4
  • 12
    • 0035461919 scopus 로고    scopus 로고
    • Antiangiogenic scheduling of lower dose cancer chemotherapy
    • Gately, S. & Kerbel, R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J. 7, 427-436 (2001).
    • (2001) Cancer J. , vol.7 , pp. 427-436
    • Gately, S.1    Kerbel, R.2
  • 13
    • 0018957499 scopus 로고
    • Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients
    • Rose, D. P. & Davis, T. E. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res. 40, 4043-4047 (1980).
    • (1980) Cancer Res. , vol.40 , pp. 4043-4047
    • Rose, D.P.1    Davis, T.E.2
  • 14
    • 0036682284 scopus 로고    scopus 로고
    • Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway
    • 324
    • Rapisarda, A. et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62, 4, 316-314, 324 (2002).
    • (2002) Cancer Res. , vol.62 , Issue.4 , pp. 316-314
    • Rapisarda, A.1
  • 15
    • 79960989122 scopus 로고    scopus 로고
    • Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors
    • Kummar, S. et al. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin. Cancer Res. 17, 5123-5131 (2011).
    • (2011) Clin. Cancer Res. , vol.17 , pp. 5123-5131
    • Kummar, S.1
  • 16
    • 70350108862 scopus 로고    scopus 로고
    • Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination
    • Radojcic, V. et al. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol. Immunother. 59, 137-148 (2010).
    • (2010) Cancer Immunol. Immunother. , vol.59 , pp. 137-148
    • Radojcic, V.1
  • 17
    • 18344375283 scopus 로고    scopus 로고
    • Immunotherapy and chemotherapy-A practical partnership
    • Lake, R. A. & Robinson, B. W. Immunotherapy and chemotherapy-a practical partnership. Nat. Rev. Cancer 5, 397-405 (2005).
    • (2005) Nat. Rev. Cancer , vol.5 , pp. 397-405
    • Lake, R.A.1    Robinson, B.W.2
  • 18
    • 50549102898 scopus 로고    scopus 로고
    • Immunogenic cancer cell death: A key-lock paradigm
    • Tesniere, A. et al. Immunogenic cancer cell death: a key-lock paradigm. Curr. Opin. Immunol. 20, 504-511 (2008).
    • (2008) Curr. Opin. Immunol. , vol.20 , pp. 504-511
    • Tesniere, A.1
  • 19
    • 68349083269 scopus 로고    scopus 로고
    • Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations
    • Kaneno, R., Shurin G. V, Tourkova, I. L. & Shurin, M. R. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J. Transl. Med. 7, 58 (2009).
    • (2009) J. Transl. Med. , vol.7 , pp. 58
    • Kaneno, R.1    Shurin, G.V.2    Tourkova, I.L.3    Shurin, M.R.4
  • 20
    • 79960920666 scopus 로고    scopus 로고
    • Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells
    • Kaneno, R. et al. Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell. Oncol. (Dordr.) 34, 97-106 (2011).
    • (2011) Cell. Oncol. (Dordr.) , vol.34 , pp. 97-106
    • Kaneno, R.1
  • 21
    • 33847368549 scopus 로고    scopus 로고
    • + regulatory T cells and restores T and NK effector functions in end stage cancer patients
    • + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56, 641-648 (2007).
    • (2007) Cancer Immunol. Immunother. , vol.56 , pp. 641-648
    • Ghiringhelli, F.1
  • 23
    • 77953730756 scopus 로고    scopus 로고
    • + regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels
    • + regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res. 70, 4850-4858 (2010).
    • (2010) Cancer Res. , vol.70 , pp. 4850-4858
    • Zhao, J.1
  • 24
    • 84872523491 scopus 로고    scopus 로고
    • Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro
    • Kan, S. et al. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res. 32, 5363-5369 (2012).
    • (2012) Anticancer Res. , vol.32 , pp. 5363-5369
    • Kan, S.1
  • 25
    • 84862120892 scopus 로고    scopus 로고
    • Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner
    • Michels, T. et al. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J. Immunotoxicol. 9, 292-300 (2012).
    • (2012) J. Immunotoxicol. , vol.9 , pp. 292-300
    • Michels, T.1
  • 26
    • 79960732805 scopus 로고    scopus 로고
    • Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity
    • Sierro, S. R. et al. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur. J. Immunol. 41, 2217-2228 (2011).
    • (2011) Eur. J. Immunol. , vol.41 , pp. 2217-2228
    • Sierro, S.R.1
  • 27
    • 84879525182 scopus 로고    scopus 로고
    • The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system
    • Geary, S. M., Lemke, C. D., Lubaroff, D. M. & Salem, A. K. The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system. PLoS ONE 8, e67904 (2013).
    • (2013) PLoS ONE , vol.8 , pp. e67904
    • Geary, S.M.1    Lemke, C.D.2    Lubaroff, D.M.3    Salem, A.K.4
  • 28
    • 84890285900 scopus 로고    scopus 로고
    • Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells
    • Todaro, M., Meraviglia, S., Caccamo, N., Stassi, G. & Dieli, F. Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells. Oncoimmunology 2, e25821 (2013).
    • (2013) Oncoimmunology , vol.2 , pp. e25821
    • Todaro, M.1    Meraviglia, S.2    Caccamo, N.3    Stassi, G.4    Dieli, F.5
  • 29
    • 15944410592 scopus 로고    scopus 로고
    • + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
    • + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105, 2862-2868 (2005).
    • (2005) Blood , vol.105 , pp. 2862-2868
    • Lutsiak, M.E.1
  • 30
    • 84860815596 scopus 로고    scopus 로고
    • Metronomic cyclophosphamide treatment in metastasized breast cancer patients: Immunological effects and clinical outcome
    • Ge, Y. et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol. Immunother. 61, 353-362 (2012).
    • (2012) Cancer Immunol. Immunother. , vol.61 , pp. 353-362
    • Ge, Y.1
  • 31
    • 84890086459 scopus 로고    scopus 로고
    • Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
    • Inoue, H. & Tani, K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 21, 39-49 (2014).
    • (2014) Cell Death Differ. , vol.21 , pp. 39-49
    • Inoue, H.1    Tani, K.2
  • 32
    • 29144530630 scopus 로고    scopus 로고
    • Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
    • Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691-1701 (2005).
    • (2005) J. Exp. Med. , vol.202 , pp. 1691-1701
    • Casares, N.1
  • 33
    • 84875600868 scopus 로고    scopus 로고
    • Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy
    • Nars, M. S. & Kaneno, R. Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int. J. Cancer 132, 2471-2478 (2013).
    • (2013) Int. J. Cancer , vol.132 , pp. 2471-2478
    • Nars, M.S.1    Kaneno, R.2
  • 34
    • 84894582150 scopus 로고    scopus 로고
    • Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas
    • Sheng Sow, H. & Mattarollo, S. R. Combining low-dose or metronomic chemotherapy with anticancer vaccines: a therapeutic opportunity for lymphomas. Oncoimmunology 2, e27058 (2013).
    • (2013) Oncoimmunology , vol.2 , pp. e27058
    • Sheng Sow, H.1    Mattarollo, S.R.2
  • 35
    • 84946487102 scopus 로고    scopus 로고
    • Multi-modal treatment with peptide vaccine metronomic cyclophosphamide and anti-PD1 monoclonal antibody provides effective control of tumors in multiple models [abstract]
    • P130 a2508
    • Weir, G. et al. Multi-modal treatment with peptide vaccine, metronomic cyclophosphamide and anti-PD1 monoclonal antibody provides effective control of tumors in multiple models [abstract]. J. Immunother. Cancer 2 (Suppl. 3), P130 a2508 (2015).
    • (2015) J. Immunother. Cancer , vol.2
    • Weir, G.1
  • 36
    • 0035865363 scopus 로고    scopus 로고
    • Redefining the target: Chemotherapeutics as antiangiogenics
    • Miller, K. D., Sweeney, C. J. & Sledge, G. W. Jr. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 19, 1195-1206 (2001).
    • (2001) J. Clin. Oncol. , vol.19 , pp. 1195-1206
    • Miller, K.D.1    Sweeney, C.J.2    Sledge, G.W.3
  • 37
    • 0035870297 scopus 로고    scopus 로고
    • The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors
    • Sweeney, C. J. et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 61, 3369-3372 (2001).
    • (2001) Cancer Res. , vol.61 , pp. 3369-3372
    • Sweeney, C.J.1
  • 39
    • 84961056499 scopus 로고
    • Natural history of untreated breast cancer (1805-1933). Comparison of untreated and treated cases according to histological grade of malignancy
    • Bloom, H. J., Richardson, W. W. & Harries, E. J. Natural history of untreated breast cancer (1805-1933). Comparison of untreated and treated cases according to histological grade of malignancy. Br. Med. J. 2, 213-221 (1962).
    • (1962) Br. Med. J. , vol.2 , pp. 213-221
    • Bloom, H.J.1    Richardson, W.W.2    Harries, E.J.3
  • 41
    • 84866597106 scopus 로고    scopus 로고
    • Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
    • Cardoso, F. et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23 (Suppl. 7), vii1-vii9 (2012).
    • (2012) Ann. Oncol. , vol.23 , pp. vii1-vii9
    • Cardoso, F.1
  • 42
    • 84869503259 scopus 로고    scopus 로고
    • The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer
    • Cardoso, F. et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur. J. Cancer. 48, 3355-3377 (2012).
    • (2012) Eur. J. Cancer. , vol.48 , pp. 3355-3377
    • Cardoso, F.1
  • 43
    • 84877147107 scopus 로고    scopus 로고
    • International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer
    • Lin, N. U. et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast 22, 203-210 (2013).
    • (2013) Breast , vol.22 , pp. 203-210
    • Lin, N.U.1
  • 44
    • 0034680102 scopus 로고    scopus 로고
    • Molecular portraits of human breast tumours
    • Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
    • (2000) Nature , vol.406 , pp. 747-752
    • Perou, C.M.1
  • 45
    • 60849097255 scopus 로고    scopus 로고
    • Gene-expression signatures in breast cancer
    • Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790-800 (2009).
    • (2009) N. Engl. J. Med. , vol.360 , pp. 790-800
    • Sotiriou, C.1    Pusztai, L.2
  • 46
    • 84861576201 scopus 로고    scopus 로고
    • The landscape of cancer genes and mutational processes in breast cancer
    • Stephens, P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404 (2012).
    • (2012) Nature , vol.486 , pp. 400-404
    • Stephens, P.J.1
  • 47
    • 84920816121 scopus 로고    scopus 로고
    • Factors responsible for long-term survival in metastatic breast cancer
    • Kontani, K. et al. Factors responsible for long-term survival in metastatic breast cancer. World J. Surg. Oncol. 12, 344 (2014).
    • (2014) World J. Surg. Oncol. , vol.12 , pp. 344
    • Kontani, K.1
  • 48
    • 84919392527 scopus 로고    scopus 로고
    • Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more
    • Kontani, K. et al. Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more. Mol. Clin. Oncol. 1, 225-230 (2013).
    • (2013) Mol. Clin. Oncol. , vol.1 , pp. 225-230
    • Kontani, K.1
  • 49
    • 0029789811 scopus 로고    scopus 로고
    • Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
    • Greenberg, P. A. et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol. 14, 2197-2205 (1996).
    • (1996) J. Clin. Oncol. , vol.14 , pp. 2197-2205
    • Greenberg, P.A.1
  • 50
    • 84907592491 scopus 로고    scopus 로고
    • The role of maintenance strategies in breast cancer
    • Munzone, E. & Colleoni, M. The role of maintenance strategies in breast cancer. Memo 7, 52-156 (2014).
    • (2014) Memo , vol.7 , pp. 52-156
    • Munzone, E.1    Colleoni, M.2
  • 52
    • 84901001797 scopus 로고    scopus 로고
    • Metronomics as maintenance treatment in oncology: Time for chemo-switch
    • Malik, P. S., Raina, V. & André, N. Metronomics as maintenance treatment in oncology: time for chemo-switch. Front. Oncol. 4, 76 (2014).
    • (2014) Front. Oncol. , vol.4 , pp. 76
    • Malik, P.S.1    Raina, V.2    André, N.3
  • 53
    • 39149083784 scopus 로고    scopus 로고
    • Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease
    • Gralow, J. R. et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J. Clin. Oncol. 26, 814-819 (2008).
    • (2008) J. Clin. Oncol. , vol.26 , pp. 814-819
    • Gralow, J.R.1
  • 54
    • 33646375742 scopus 로고    scopus 로고
    • Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update
    • Kaufmann, M. et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J. Clin. Oncol. 24, 1940-1949 (2006).
    • (2006) J. Clin. Oncol. , vol.24 , pp. 1940-1949
    • Kaufmann, M.1
  • 55
    • 2642517065 scopus 로고    scopus 로고
    • Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast April 26-28 2003 Philadelphia, Pennsylvania
    • Schwartz, G. F. & Hortobagyi, G. N. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer 100, 2512-2532 (2004).
    • (2004) Cancer , vol.100 , pp. 2512-2532
    • Schwartz, G.F.1    Hortobagyi, G.N.2
  • 56
    • 84918578552 scopus 로고    scopus 로고
    • Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy
    • Ebos, J. M. et al. Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. EMBO Mol. Med. 6, 1561-1576 (2014).
    • (2014) EMBO Mol. Med. , vol.6 , pp. 1561-1576
    • Ebos, J.M.1
  • 57
    • 60649106195 scopus 로고    scopus 로고
    • Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
    • Pàez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
    • (2009) Cancer Cell , vol.15 , pp. 220-231
    • Pàez-Ribes, M.1
  • 58
    • 60649087564 scopus 로고    scopus 로고
    • Accelerated Metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
    • Ebos, J. M. et al. Accelerated Metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239 (2009).
    • (2009) Cancer Cell , vol.15 , pp. 232-239
    • Ebos, J.M.1
  • 59
    • 69349097400 scopus 로고    scopus 로고
    • Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy
    • Ebos, J. M., Lee, C. R. & Kerbel, R. S. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin. Cancer Res. 15, 5020-5025 (2009).
    • (2009) Clin. Cancer Res. , vol.15 , pp. 5020-5025
    • Ebos, J.M.1    Lee, C.R.2    Kerbel, R.S.3
  • 60
    • 84907597678 scopus 로고    scopus 로고
    • A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer
    • Masuda, N. et al. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer. Cancer Chemother. Pharmacol. 74, 229-238 (2014).
    • (2014) Cancer Chemother. Pharmacol. , vol.74 , pp. 229-238
    • Masuda, N.1
  • 61
    • 79960616984 scopus 로고    scopus 로고
    • Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer
    • Dellapasqua, S. et al. Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. Breast 20, 319-323 (2011).
    • (2011) Breast , vol.20 , pp. 319-323
    • Dellapasqua, S.1
  • 62
    • 33747032320 scopus 로고    scopus 로고
    • Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients
    • Bottini, A. et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J. Clin. Oncol. 24, 3623-3628 (2006).
    • (2006) J. Clin. Oncol. , vol.24 , pp. 3623-3628
    • Bottini, A.1
  • 63
    • 77957556802 scopus 로고    scopus 로고
    • Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: Results of the randomized ALCL99-vinblastine trial
    • Le Deley, M.-C. et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J. Clin. Oncol. 28, 3987-3993 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , pp. 3987-3993
    • Le Deley, M.-C.1
  • 64
    • 33646267928 scopus 로고    scopus 로고
    • From total empiricism to a rational design of metronomic chemotherapy phase i dosing trials
    • Lam, T., Hetherington, J. W., Greenman, J. & Maraveyas, A. From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials. Anticancer Drugs 17, 113-121 (2006).
    • (2006) Anticancer Drugs , vol.17 , pp. 113-121
    • Lam, T.1    Hetherington, J.W.2    Greenman, J.3    Maraveyas, A.4
  • 65
    • 84875514759 scopus 로고    scopus 로고
    • Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are not suitable for a "standard chemotherapy regimen": The CASA randomized trial
    • Crivellari, D. et al. Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are not suitable for a "standard chemotherapy regimen": the CASA randomized trial. Breast 22, 130-137 (2013).
    • (2013) Breast , vol.22 , pp. 130-137
    • Crivellari, D.1
  • 66
    • 74849108808 scopus 로고    scopus 로고
    • Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: A pooled analysis of two randomized controlled trials (N.SAS-BC 01 trial and CUBC trial)
    • Ohashi, Y. et al. Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N.SAS-BC 01 trial and CUBC trial). Breast Cancer Res. Treat. 119, 633-641 (2010).
    • (2010) Breast Cancer Res. Treat. , vol.119 , pp. 633-641
    • Ohashi, Y.1
  • 67
    • 0037265484 scopus 로고    scopus 로고
    • Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer
    • Kasumi, F. et al. Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer. Oncology 64, 146-153 (2003).
    • (2003) Oncology , vol.64 , pp. 146-153
    • Kasumi, F.1
  • 68
    • 63049102784 scopus 로고    scopus 로고
    • Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial
    • Watanabe, T. et al. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. J. Clin. Oncol. 27, 1368-1374 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , pp. 1368-1374
    • Watanabe, T.1
  • 69
    • 68749100902 scopus 로고    scopus 로고
    • Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage, I, II, or IIIA lymph node-positive breast cancer: A comparative study
    • Park, Y. et al. Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage, I, II, or IIIA lymph node-positive breast cancer: a comparative study. Br. J. Cancer 101, 598-604 (2009).
    • (2009) Br. J. Cancer , vol.101 , pp. 598-604
    • Park, Y.1
  • 70
    • 84996488149 scopus 로고    scopus 로고
    • Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC) [abstract]
    • Colleoni, M. et al. Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC) [abstract]. J. Clin. Oncol. 33, a1002 (2015).
    • (2015) J. Clin. Oncol. , vol.33 , pp. a1002
    • Colleoni, M.1
  • 71
    • 31544441697 scopus 로고    scopus 로고
    • Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: Antitumor activity and biological effects
    • Colleoni, M. et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann. Oncol. 17, 232-238 (2006).
    • (2006) Ann. Oncol. , vol.17 , pp. 232-238
    • Colleoni, M.1
  • 72
    • 77649221837 scopus 로고    scopus 로고
    • Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response
    • Wong, N. S. et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J. Clin. Oncol. 28, 723-730 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , pp. 723-730
    • Wong, N.S.1
  • 73
    • 0033050165 scopus 로고    scopus 로고
    • Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
    • Blum, J. L. et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 17, 485-493 (1999).
    • (1999) J. Clin. Oncol. , vol.17 , pp. 485-493
    • Blum, J.L.1
  • 74
    • 0035498748 scopus 로고    scopus 로고
    • Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma
    • Zelek, L. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92, 2267-2272 (2001).
    • (2001) Cancer , vol.92 , pp. 2267-2272
    • Zelek, L.1
  • 75
    • 0031944611 scopus 로고    scopus 로고
    • Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts
    • Sawada, N. et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin. Cancer Res. 4, 1013-1019 (1998).
    • (1998) Clin. Cancer Res. , vol.4 , pp. 1013-1019
    • Sawada, N.1
  • 76
    • 0032856558 scopus 로고    scopus 로고
    • Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models
    • Endo, M. et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int. J. Cancer 83, 127-134 (1999).
    • (1999) Int. J. Cancer , vol.83 , pp. 127-134
    • Endo, M.1
  • 77
    • 84856714423 scopus 로고    scopus 로고
    • An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline-and taxane-pretreated metastatic breast cancer: A phase II study
    • Wang, Z. et al. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline-and taxane-pretreated metastatic breast cancer: a phase II study. Cancer Chemother. Pharmacol. 69, 515-522 (2012).
    • (2012) Cancer Chemother. Pharmacol. , vol.69 , pp. 515-522
    • Wang, Z.1
  • 78
    • 82255177129 scopus 로고    scopus 로고
    • Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: A retrospective review of capecitabine for metastatic breast cancer
    • Leonard, R., Hennessy, B. T., Blum, J. L. & O'Shaughnessy, J. Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. Clin. Breast Cancer 11, 349-356 (2011).
    • (2011) Clin. Breast Cancer , vol.11 , pp. 349-356
    • Leonard, R.1    Hennessy, B.T.2    Blum, J.L.3    O'Shaughnessy, J.4
  • 79
    • 83255191654 scopus 로고    scopus 로고
    • Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer
    • Fedele, P. et al. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Eur. J. Cancer 48, 24-29 (2012).
    • (2012) Eur. J. Cancer , vol.48 , pp. 24-29
    • Fedele, P.1
  • 80
    • 83355163402 scopus 로고    scopus 로고
    • Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer
    • Stockler, M. R. et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J. Clin. Oncol. 29, 4498-4504 (2011).
    • (2011) J. Clin. Oncol. , vol.29 , pp. 4498-4504
    • Stockler, M.R.1
  • 81
    • 36549050900 scopus 로고    scopus 로고
    • Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer
    • O'Brien, M. E. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 19, 1-7 (2008).
    • (2008) Anticancer Drugs , vol.19 , pp. 1-7
    • O'Brien, M.E.1
  • 82
    • 0036096806 scopus 로고    scopus 로고
    • Liposome-based drug delivery in breast cancer treatment
    • Park, J. W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 4, 95-99 (2002).
    • (2002) Breast Cancer Res. , vol.4 , pp. 95-99
    • Park, J.W.1
  • 83
    • 77951885289 scopus 로고    scopus 로고
    • Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report
    • Munzone, E. et al. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. Breast 19, 33-37 (2010).
    • (2010) Breast , vol.19 , pp. 33-37
    • Munzone, E.1
  • 84
    • 0029802685 scopus 로고    scopus 로고
    • The microtubule-affecting drug paclitaxel has antiangiogenic activity
    • Belotti, D. et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2, 1843-1849 (1996).
    • (1996) Clin. Cancer Res. , vol.2 , pp. 1843-1849
    • Belotti, D.1
  • 85
    • 0038105608 scopus 로고    scopus 로고
    • Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): Association with impaired repositioning of the microtubule organizing center
    • Hotchkiss, K. A. et al. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol. Cancer Ther. 1, 1191-1200 (2002).
    • (2002) Mol. Cancer Ther. , vol.1 , pp. 1191-1200
    • Hotchkiss, K.A.1
  • 86
    • 0032762952 scopus 로고    scopus 로고
    • Antiangiogenesis is produced by nontoxic doses of vinblastine
    • Vacca, A. et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94, 4143-4155 (1999).
    • (1999) Blood , vol.94 , pp. 4143-4155
    • Vacca, A.1
  • 87
    • 84878235787 scopus 로고    scopus 로고
    • Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: A hellenic cooperative oncology group clinical translational study
    • Briasoulis, E. et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer 13, 263 (2013).
    • (2013) BMC Cancer , vol.13 , pp. 263
    • Briasoulis, E.1
  • 88
    • 82455171934 scopus 로고    scopus 로고
    • Phase i trial of metronomic oral vinorelbine in patients with advanced cancer
    • Rajdev, L. et al. Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemother. Pharmacol. 68, 1119-1124 (2011).
    • (2011) Cancer Chemother. Pharmacol. , vol.68 , pp. 1119-1124
    • Rajdev, L.1
  • 89
    • 70350212970 scopus 로고    scopus 로고
    • Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer
    • Briasoulis, E. et al. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin. Cancer Res. 15, 6454-6461 (2009).
    • (2009) Clin. Cancer Res. , vol.15 , pp. 6454-6461
    • Briasoulis, E.1
  • 90
    • 77955616240 scopus 로고    scopus 로고
    • Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer
    • Addeo, R. et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin. Breast Cancer 10, 301-306 (2010).
    • (2010) Clin. Breast Cancer , vol.10 , pp. 301-306
    • Addeo, R.1
  • 91
    • 84856692921 scopus 로고    scopus 로고
    • A phase i trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer
    • Saridaki, Z. et al. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. Cancer Chemother. Pharmacol. 69, 35-42 (2012).
    • (2012) Cancer Chemother. Pharmacol. , vol.69 , pp. 35-42
    • Saridaki, Z.1
  • 92
    • 84907361692 scopus 로고    scopus 로고
    • Metronomics chemotherapy: Time for computational decision support
    • Barbolosi, D. et al. Metronomics chemotherapy: time for computational decision support. Cancer Chemother. Pharmacol. 74, 647-652 (2014).
    • (2014) Cancer Chemother. Pharmacol. , vol.74 , pp. 647-652
    • Barbolosi, D.1
  • 93
    • 84867574450 scopus 로고    scopus 로고
    • Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases
    • Addeo, R. et al. Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemother. Pharmacol. 70, 603-609 (2012).
    • (2012) Cancer Chemother. Pharmacol. , vol.70 , pp. 603-609
    • Addeo, R.1
  • 94
    • 33749416983 scopus 로고    scopus 로고
    • Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
    • Orlando, L. et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 6, 225 (2006).
    • (2006) BMC Cancer , vol.6 , pp. 225
    • Orlando, L.1
  • 95
    • 33744973643 scopus 로고    scopus 로고
    • Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: A randomized phase II study [abstract 4]
    • Burstein, H. J. et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study [abstract 4]. 28th Annual San Antonio Breast Cancer Symposium (2005).
    • (2005) 28th Annual San Antonio Breast Cancer Symposium
    • Burstein, H.J.1
  • 96
    • 54449099774 scopus 로고    scopus 로고
    • Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
    • Dellapasqua, S. et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J. Clin. Oncol. 26, 4899-4905 (2008).
    • (2008) J. Clin. Oncol. , vol.26 , pp. 4899-4905
    • Dellapasqua, S.1
  • 97
    • 85021659876 scopus 로고    scopus 로고
    • SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer-A multicenter randomized phase III trial [abstract]
    • Rochlitz, C. et al. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer-a multicenter, randomized phase III trial [abstract]. J. Clin. Oncol. 32 (5s Suppl.), a518 (2014).
    • (2014) J. Clin. Oncol. , vol.32 , Issue.5 , pp. A518
    • Rochlitz, C.1
  • 98
    • 84861111904 scopus 로고    scopus 로고
    • Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: Clinical and biological activity
    • Montagna, E. et al. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin. Breast Cancer 12, 207-214 (2012).
    • (2012) Clin. Breast Cancer , vol.12 , pp. 207-214
    • Montagna, E.1
  • 99
    • 57049164414 scopus 로고    scopus 로고
    • Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline-and taxane-refractory breast cancer
    • García-Sáenz, J. A., et al. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline-and taxane-refractory breast cancer. J. Chemother. 20, 632-639 (2008).
    • (2008) J. Chemother. , vol.20 , pp. 632-639
    • García-Sáenz, J.A.1
  • 101
    • 0034026144 scopus 로고    scopus 로고
    • Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines
    • Hida, T. et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 6, 2006-2011 (2000).
    • (2000) Clin. Cancer Res. , vol.6 , pp. 2006-2011
    • Hida, T.1
  • 102
    • 0037086261 scopus 로고    scopus 로고
    • Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ
    • Half, E. et al. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 62, 1676-1681 (2002).
    • (2002) Cancer Res. , vol.62 , pp. 1676-1681
    • Half, E.1
  • 103
    • 0036301285 scopus 로고    scopus 로고
    • Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: Structure-activity relationships and their implications
    • Cassidy, P. B., Moos, P. J., Kelly, R. C. & Fitzpatrick, F. A. Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications. Clin. Cancer Res. 8, 846-855 (2002).
    • (2002) Clin. Cancer Res. , vol.8 , pp. 846-855
    • Cassidy, P.B.1    Moos, P.J.2    Kelly, R.C.3    Fitzpatrick, F.A.4
  • 104
    • 78751630984 scopus 로고    scopus 로고
    • Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas
    • Mainetti, L. E., Rozados, V. R., Rossa, A., Bonfil, R. D. & Scharovsky, O. G. Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas. J. Cancer Res. Clin. Oncol. 137, 151-163 (2011).
    • (2011) J. Cancer Res. Clin. Oncol. , vol.137 , pp. 151-163
    • Mainetti, L.E.1    Rozados, V.R.2    Rossa, A.3    Bonfil, R.D.4    Scharovsky, O.G.5
  • 105
    • 84874856960 scopus 로고    scopus 로고
    • Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
    • Perroud, H. A. et al. Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. Future Oncol. 9, 451-462 (2013).
    • (2013) Future Oncol. , vol.9 , pp. 451-462
    • Perroud, H.A.1
  • 106
    • 84859478512 scopus 로고    scopus 로고
    • Phase II trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer
    • Young, S. D., Lafrenie, R. M. & Clemons, M. J. Phase II trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer. Curr. Oncol. 19, e75-e83 (2012).
    • (2012) Curr. Oncol. , vol.19 , pp. e75-e83
    • Young, S.D.1    Lafrenie, R.M.2    Clemons, M.J.3
  • 107
    • 84866078348 scopus 로고    scopus 로고
    • Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: A mono-institutional case-cohort report
    • Aurilio, G. et al. Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: A mono-institutional case-cohort report. Breast J. 18, 470-474 (2012).
    • (2012) Breast J. , vol.18 , pp. 470-474
    • Aurilio, G.1
  • 108
    • 78650253350 scopus 로고    scopus 로고
    • Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate
    • Licchetta, A. et al. Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate. J. Chemother. 22, 201-204 (2010).
    • (2010) J. Chemother. , vol.22 , pp. 201-204
    • Licchetta, A.1
  • 109
    • 84892811705 scopus 로고    scopus 로고
    • Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive HER2-negative metastatic breast cancer
    • Schwartzberg, L. S. et al. Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Clin. Breast Cancer 14, 13-19 (2014).
    • (2014) Clin. Breast Cancer , vol.14 , pp. 13-19
    • Schwartzberg, L.S.1
  • 110
    • 84879798525 scopus 로고    scopus 로고
    • Metronomic cyclophosphamide and methotrexate chemotherapy combined with 1E10 anti-idiotype vaccine in metastatic breast cancer
    • Soriano, J. L. et al. Metronomic cyclophosphamide and methotrexate chemotherapy combined with 1E10 anti-idiotype vaccine in metastatic breast cancer. Int. J. Breast Cancer 2011, 710292 (2011).
    • (2011) Int. J. Breast Cancer , vol.2011 , pp. 710292
    • Soriano, J.L.1
  • 111
    • 84946475349 scopus 로고    scopus 로고
    • US National Library of Medicine. ClinicalTrials.gov [online]
    • US National Library of Medicine. ClinicalTrials.gov [online], https://www.clinicaltrials.gov/ct2/show/NCT01112826?term=NCT01112826&rank=1 (2015).
    • (2015)
  • 112
    • 84946475466 scopus 로고    scopus 로고
    • US National Library of Medicine. ClinicalTrials.gov [online]
    • US National Library of Medicine. ClinicalTrials.gov [online], https://www.clinicaltrials.gov/ct2/show/NCT02012634?term=NCT02012634&rank=1 (2014).
    • (2014)
  • 113
    • 84946475764 scopus 로고    scopus 로고
    • US National Library of Medicine. ClinicalTrials.gov [online]
    • US National Library of Medicine. ClinicalTrials.gov [online], https://www.clinicaltrials.gov/ct2/show/NCT01917279?term=NCT01917279&rank=1 (2013).
    • (2013)
  • 114
    • 84946485482 scopus 로고    scopus 로고
    • US National Library of Medicine. ClinicalTrials.gov [online]
    • US National Library of Medicine. ClinicalTrials.gov [online], https://www.clinicaltrials.gov/ct2/show/NCT01131195?term=NCT01131195&rank=1 (2015).
    • (2015)
  • 115
    • 0034778395 scopus 로고    scopus 로고
    • Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy
    • Harris, A. L. et al. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin. Cancer Res. 7, 1992-1997 (2001).
    • (2001) Clin. Cancer Res. , vol.7 , pp. 1992-1997
    • Harris, A.L.1
  • 116
    • 34547779489 scopus 로고    scopus 로고
    • Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins
    • Deprimo, S. E. et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J. Transl. Med. 5, 32 (2007).
    • (2007) J. Transl. Med. , vol.5 , pp. 32
    • Deprimo, S.E.1
  • 117
    • 0041589524 scopus 로고    scopus 로고
    • Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells
    • Bertolini, F. et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 63, 4342-4346 (2003).
    • (2003) Cancer Res. , vol.63 , pp. 4342-4346
    • Bertolini, F.1
  • 118
    • 19944432454 scopus 로고    scopus 로고
    • Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis
    • Shaked, Y. et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7, 101-111 (2005).
    • (2005) Cancer Cell , vol.7 , pp. 101-111
    • Shaked, Y.1
  • 119
    • 27644436870 scopus 로고    scopus 로고
    • Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
    • Shaked, Y. et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106, 3058-3061 (2005).
    • (2005) Blood , vol.106 , pp. 3058-3061
    • Shaked, Y.1
  • 120
    • 33745939679 scopus 로고    scopus 로고
    • Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
    • Mancuso, P. et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108, 452-459 (2006).
    • (2006) Blood , vol.108 , pp. 452-459
    • Mancuso, P.1
  • 121
    • 55949102088 scopus 로고    scopus 로고
    • Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER-and/or PgR-positive breast cancer: Clinical and biological activity
    • Torrisi, R. et al. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER-and/or PgR-positive breast cancer: clinical and biological activity. Br. J. Cancer 99, 1564-1571 (2008).
    • (2008) Br. J. Cancer , vol.99 , pp. 1564-1571
    • Torrisi, R.1
  • 122
    • 79958054297 scopus 로고    scopus 로고
    • Circulating endothelial progenitor cells in metronomic chemotherapy using irinotecan and/or bevacizumab for colon carcinoma: Study of their clinical significance
    • Murakami, H., Ogata, Y., Akagi, Y., Ishibashi, N. & Shirouzu, K. Circulating endothelial progenitor cells in metronomic chemotherapy using irinotecan and/or bevacizumab for colon carcinoma: study of their clinical significance. Exp. Ther. Med. 2, 595-600 (2011).
    • (2011) Exp. Ther. Med. , vol.2 , pp. 595-600
    • Murakami, H.1    Ogata, Y.2    Akagi, Y.3    Ishibashi, N.4    Shirouzu, K.5
  • 123
    • 78649465366 scopus 로고    scopus 로고
    • Cellular and soluble markers of tumor angiogenesis: From patient selection to the identification of the most appropriate postresistance therapy
    • Bertolini, F., Marighetti, P. & Shaked, Y. Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy. Biochim. Biophys. Acta 1806, 131-137 (2010).
    • (2010) Biochim. Biophys. Acta , vol.1806 , pp. 131-137
    • Bertolini, F.1    Marighetti, P.2    Shaked, Y.3
  • 124
    • 84862570397 scopus 로고    scopus 로고
    • Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab
    • Dellapasqua, S. et al. Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. Breast 21, 309-313 (2012).
    • (2012) Breast , vol.21 , pp. 309-313
    • Dellapasqua, S.1
  • 125
    • 85018227233 scopus 로고    scopus 로고
    • Generation of a plasma microRNA (miRNA) signature predicting response to metronomic chemotherapy (MC) for advanced breast cancer (ABC) [abstract]
    • Emmenegger, U. et al. Generation of a plasma microRNA (miRNA) signature predicting response to metronomic chemotherapy (MC) for advanced breast cancer (ABC) [abstract]. Ann. Oncol. 25 (Suppl. 4), 178P (2014).
    • (2014) Ann. Oncol. , vol.25 , pp. 178P
    • Emmenegger, U.1
  • 126
    • 84872084645 scopus 로고    scopus 로고
    • Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models
    • Hackl, C. et al. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 62, 259-271 (2013).
    • (2013) Gut , vol.62 , pp. 259-271
    • Hackl, C.1
  • 127
    • 79952367827 scopus 로고    scopus 로고
    • Metronomic S-1 chemotherapy and vandetanib: An efficacious and nontoxic treatment for hepatocellular carcinoma
    • Iwamoto, H. et al. Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. Neoplasia 13, 187-197 (2011).
    • (2011) Neoplasia , vol.13 , pp. 187-197
    • Iwamoto, H.1
  • 128
    • 20344374970 scopus 로고    scopus 로고
    • High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults
    • Le Deley, M.-C. et al. High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr. Blood Cancer 45, 25-31 (2005).
    • (2005) Pediatr. Blood Cancer , vol.45 , pp. 25-31
    • Le Deley, M.-C.1
  • 129
    • 26844477930 scopus 로고    scopus 로고
    • Secondary Ph+ acute lymphoblastic leukemia after temozolomide
    • De Vita, S. et al. Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann. Hematol. 84, 760-762 (2005).
    • (2005) Ann. Hematol. , vol.84 , pp. 760-762
    • De Vita, S.1
  • 130
    • 74049087050 scopus 로고    scopus 로고
    • Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer
    • Eichhorn, M. E. et al. Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int. J. Cancer 126, 1235-1245 (2010).
    • (2010) Int. J. Cancer , vol.126 , pp. 1235-1245
    • Eichhorn, M.E.1
  • 131
    • 10744233861 scopus 로고    scopus 로고
    • Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy
    • Pastorino, F. et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 63, 7400-7409 (2003).
    • (2003) Cancer Res. , vol.63 , pp. 7400-7409
    • Pastorino, F.1
  • 132
    • 84874988983 scopus 로고    scopus 로고
    • The use of nanoparticulate delivery systems in metronomic chemotherapy
    • Yu, D.-H. et al. The use of nanoparticulate delivery systems in metronomic chemotherapy. Biomaterials 34, 3925-3937 (2013).
    • (2013) Biomaterials , vol.34 , pp. 3925-3937
    • Yu, D.-H.1
  • 133
    • 84884487240 scopus 로고    scopus 로고
    • Precision medicine for cancer patients: Lessons learned and the path forward
    • Gazdar, A. F. & Minna, J. D. Precision medicine for cancer patients: lessons learned and the path forward. J. Natl Cancer Inst. 105, 1262-1263 (2013).
    • (2013) J. Natl Cancer Inst. , vol.105 , pp. 1262-1263
    • Gazdar, A.F.1    Minna, J.D.2
  • 134
    • 84863924314 scopus 로고    scopus 로고
    • Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: A current perspective
    • Le, D. T. & Jaffee, E. M. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 72, 3439-3444 (2012).
    • (2012) Cancer Res. , vol.72 , pp. 3439-3444
    • Le, D.T.1    Jaffee, E.M.2
  • 135
    • 84902504669 scopus 로고    scopus 로고
    • Trial Watch
    • Vacchelli, E. et al. Trial Watch. Oncoimmunology 3, e27878 (2014).
    • (2014) Oncoimmunology , vol.3 , pp. e27878
    • Vacchelli, E.1
  • 136
    • 80052420081 scopus 로고    scopus 로고
    • Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus
    • Cerullo, V. et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol. Ther. 19, 1737-1746 (2011).
    • (2011) Mol. Ther. , vol.19 , pp. 1737-1746
    • Cerullo, V.1
  • 137
    • 84876954809 scopus 로고    scopus 로고
    • Has the time come for metronomics in low-income and middle-income countries?
    • André, N., Banavali, S., Snihur, Y. & Pasquier, E. Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol. 14, e239-e248 (2013).
    • (2013) Lancet Oncol. , vol.14 , pp. e239-e248
    • André, N.1    Banavali, S.2    Snihur, Y.3    Pasquier, E.4
  • 138
    • 84946483934 scopus 로고    scopus 로고
    • Metronomics Global Health Initiative
    • Metronomics Global Health Initiative. http://metronomics.newethicalbusiness.org/.
  • 140
    • 78649636842 scopus 로고    scopus 로고
    • Up-to-date estimates of breast cancer survival for the years 2000-2004 in 11 European countries: The role of screening and a comparison with data from the United States
    • Rosso, S. et al. Up-to-date estimates of breast cancer survival for the years 2000-2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur. J. Cancer 46, 3351-3357 (2010).
    • (2010) Eur. J. Cancer , vol.46 , pp. 3351-3357
    • Rosso, S.1
  • 141
    • 0033619959 scopus 로고    scopus 로고
    • Underrepresentation of patients 65 years of age or older in cancer-treatment trials
    • Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A. & Albain, K. S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 341, 2061-2067 (1999).
    • (1999) N. Engl. J. Med. , vol.341 , pp. 2061-2067
    • Hutchins, L.F.1    Unger, J.M.2    Crowley, J.J.3    Coltman, C.A.4    Albain, K.S.5
  • 142
    • 84859140429 scopus 로고    scopus 로고
    • Management of elderly patients with breast cancer: Updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)
    • Biganzoli, L. et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 13, e148-e160 (2012).
    • (2012) Lancet Oncol. , vol.13 , pp. e148-e160
    • Biganzoli, L.1
  • 143
    • 84930732324 scopus 로고    scopus 로고
    • On and off metronomic oral vinorelbine in elderly women with advanced breast cancer
    • De Iuliis, F., Salerno, G., Taglieri, L., Lanza, R. & Scarpa, S. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer. Tumori 101, 30-35 (2015).
    • (2015) Tumori , vol.101 , pp. 30-35
    • De Iuliis, F.1    Salerno, G.2    Taglieri, L.3    Lanza, R.4    Scarpa, S.5
  • 144
    • 33646202671 scopus 로고    scopus 로고
    • Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: Comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring
    • Crivellari, D. et al. Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. Ann. Oncol. 17, 807-812 (2006).
    • (2006) Ann. Oncol. , vol.17 , pp. 807-812
    • Crivellari, D.1
  • 145
    • 18544408146 scopus 로고    scopus 로고
    • Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients
    • Toffoli, G. et al. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. Clin. Cancer Res. 6, 2279-2287 (2000).
    • (2000) Clin. Cancer Res. , vol.6 , pp. 2279-2287
    • Toffoli, G.1
  • 146
    • 13444272948 scopus 로고    scopus 로고
    • A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer
    • Gupta, S. et al. A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer. Am. J. Clin. Oncol. 28, 65-69 (2005).
    • (2005) Am. J. Clin. Oncol. , vol.28 , pp. 65-69
    • Gupta, S.1
  • 147
    • 84867131803 scopus 로고    scopus 로고
    • Triple-negative breast cancer in the older population
    • Aapro, M. & Wildiers, H. Triple-negative breast cancer in the older population. Ann. Oncol. 23 (Suppl. 6), vi52-vi55 (2012).
    • (2012) Ann. Oncol. , vol.23 , pp. vi52-vi55
    • Aapro, M.1    Wildiers, H.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.